Good news for epileptics in China! The new generation antiepileptic drug fycompa of Weicai has been approved by China for epilepsy patients aged ≥ 12 years!

October 17, 2019 / BIOON / - Japanese pharmaceutical company Eisai recently announced that the National Drug Administration of China (nmpa) has approved the new generation of antiepileptic drug fycompa (perampanel, pirampanel), as an adjuvant therapy, for the treatment of epilepsy distributed to the epilepsy Department of 12-year-old and above Fycompa's new drug application (NDA) was submitted in September 2018 Due to its significant clinical benefits with existing drugs, nmpa granted fycompa the priority review qualification in January 2019 It is estimated that there are about 9 million epileptics in China, about 60% of them are affected by partial epilepsy, and 40% of them need adjuvant treatment About 30% of epileptic patients received AEDs which were available on the market and could not control epileptic seizures, so there was a significant unmet medical demand in this field Fycompa is a first in class antiepileptic drug (AEDs) developed by Weicai It is a highly selective and non competitive AMPA type glutamate receptor antagonist Glutamate is the main neurotransmitter of epilepsy As an AMPA receptor antagonist, fycompa can reduce the hyperactivity of epilepsy related neurons by targeting the activity of postsynaptic AMPA receptor glutamate, which is different from the current market antiepileptic drugs (AEDs) Up to now, fycompa has been approved by more than 60 countries in the world As an adjuvant therapy, fycompa is used for the treatment of partial epilepsy (POS, with or without secondary systemic epilepsy) in patients aged 12 and over In addition, fycompa has also been approved by more than 55 countries in the world as an adjuvant therapy for the treatment of primary generalized tonic clonus (pgtc) seizures in patients aged 12 and over In the United States, fycompa is also suitable as a single drug therapy and adjuvant therapy for partial epilepsy (with or without secondary systemic epilepsy) in patients aged 4 years and over At present, Weicai is also carrying out a global phase III clinical study (study 338) to evaluate the treatment of Lennox Gastaut syndrome related epilepsy with fycompa Epilepsy is one of the most common neurological diseases in the world There are about 3.4 million patients in the United States, 1 million in Japan, 6 million in Europe, 9 million in China and 60 million in the world About 30% of patients can't control their condition with AEDs, so there is a huge medical demand in this field Epilepsy can be roughly classified according to its seizure types, in which partial seizures account for about 60% of epileptic cases and systemic seizures account for about 40% Primary generalized tonic clonic (pgtc) seizures, or grand mal, are the most common and severe types of generalized seizures, accounting for about 60% of the total seizure cases Pgtc seizures are characterized by loss of consciousness and general convulsions The main symptoms of major epileptic seizures are foaming at the mouth, eyes turning up, limbs twitching, screaming and so on, which can cause incontinence of stool and urine and persistent seizures Epilepsy is the result of the imbalance of brain neurons' stimulation and inhibition These imbalances may be caused by a variety of neurochemical mechanisms, but little is known at present Source of the original text: new drag approximate for fycompa ® for adaptive treatment of partial onsequences in China